Moderna is leveraging artificial intelligence extensively to accelerate drug development, including a hantavirus vaccine. Since partnering with OpenAI in 2023, Moderna has deployed over 750 AI models to streamline scientific and operational workflows, drastically reducing time and personnel needs. Their AI tools help analyze clinical trial data and support legal and communication tasks, enabling the company to aim for 15 new products in five years, a pace rarely seen in the pharmaceutical industry. This approach could bring faster solutions to deadly diseases like hantavirus, which has high fatality rates for some strains.
INmune Bio has become a founding member of the American Biotech Innovation Alliance (ABIA), a coalition of 26 biotech companies aiming to develop a national strategy to maintain US leadership in biotechnology. The alliance will focus on key industry ...
FDA Commissioner Marty Makary has resigned, ending a turbulent tenure marked by internal dysfunction and criticism from drugmakers, physicians, and patient groups. His leadership faced backlash over regulatory decisions, including rejections of rare ...
Moderna's stock has rallied following news of its early-stage hantavirus vaccine research. The biotech company is conducting pre-clinical work with the U.S. Army and has partnered since 2024 with the Vaccine Innovation Center at Korea University Coll...
Moderna's stock has gained more than 16% in five days following reports of its early-stage hantavirus vaccine development. The company is expanding its infectious disease research pipeline, although hantavirus's commercial potential is limited due to...
Moderna's stock rose about 6% following reports of a Hantavirus outbreak and the company's early-stage mRNA vaccine research targeting the virus. This surge extends Moderna's strong 2026 performance, with shares up 95% year-to-date, outperforming Pfi...
